Previously, CD248 was found to be expressed specifically in pericytes, cancer-associated fibroblasts (CAFs), and some tumor cells, such as sarcomas, with very low or limited expression in normal tissue; therefore, CD248 has been considered as a specific target for cancer therapy (Bagley et al. 2008; MacFadyen et al. 2005; O'Shannessy et al. 2016; Rouleau et al. 2008). Here, CD248 is linked to sarcoma.